Oncobiologics (ONS) Stock Rating Upgraded by ValuEngine

ValuEngine upgraded shares of Oncobiologics (NASDAQ:ONS) from a hold rating to a buy rating in a report issued on Thursday morning.

ONS traded up $0.01 during midday trading on Thursday, reaching $0.90. The company had a trading volume of 400 shares, compared to its average volume of 9,019. Oncobiologics has a 1 year low of $0.77 and a 1 year high of $1.53.

Oncobiologics (NASDAQ:ONS) last issued its quarterly earnings results on Tuesday, August 14th. The company reported ($0.21) EPS for the quarter. The business had revenue of $0.77 million during the quarter.

About Oncobiologics

Oncobiologics, Inc, a clinical-stage biopharmaceutical company, focuses on identifying, developing, manufacturing, and commercializing complex biosimilar therapeutics in immunology and oncology disease areas. Its advanced product candidate is ONS-3010, an adalimumab biosimilar that is in a Phase 1 clinical trial, which targets the tumor necrosis factor alpha.

See Also: What are the Benefits of Index Funds?

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Oncobiologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncobiologics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply